Search
Bio-Techne Corp
TECHAdd to Watchlist
72.160USD
+0.010+0.01%
Market hours （ET）Quotes delayed by 15 min
11.29BMarket Cap
102.25P/E TTM
Forecast
Currency: USD Updated: 2026-08-11The current earnings forecast score of Bio-Techne Corp is 6.63, ranking 323 out of 387 in the Biotechnology & Medical Research industry. The average price target is 70.00, with a high of 75.00 and a low of 60.00.
Analyst Rating
Based on
16
analysts
Hold
Current Rating
70.093
Target Price
-3.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Bio-Techne Corp
TECH
16
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Bio-Techne Corp's expected revenue for the next quarter?
Bio-Techne Corp's expected revenue is 314.68M.
What is Bio-Techne Corp's price target?
Analysts forecast that Bio-Techne Corp's price target is USD 70.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 60.00.
How have Bio-Techne CorpTECH's recent earnings per share performed?
The market expectation was USD 0.33, while Bio-Techne CorpTECH's earnings per share (EPS) for the previous quarter was USD 0.24. EPS for the next quarter is expected at USD 0.52.
What is the analyst rating for Bio-Techne Corp?
Based on the ratings of Bio-Techne Corp's stock from 16 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.